Effectiveness and tolerability of the thyme/ivy herbal fluid extract BNO 1200 for the treatment of acute cough: an observational pharmacy-based study

Figures & data

Table 1. Participant demographics and baseline characteristics.

Demographics and baseline characteristics	BNO 1200 N = 730
Gender, N (%)*
Male	239 (32.8)
Female	489 (67.2)
Age (years)
Mean ± SD	45.1 ± 15.0
Median (range)	45.0 (18.0, 88.0)
18–64 years, N (%)	654 (89.6)
≥65 years, N (%)	76 (10.4)
Smoking status, N (%)*
Regular smoker (daily)	80 (11.0)
Occasional smoker	85 (11.7)
Ex-smoker	77 (10.6)
Non-smoker	483 (66.6)
Symptom duration, N (%)*
1–2 days	268 (36.8)
3–6 days	299 (41.1)
1–2 weeks	110 (15.1)
>2 weeks	51 (7.0)
Bronchitis Severity Score, mean ± SD
Total score	8.7 ± 3.8
Cough	2.8 ± 0.8
Sputum	1.9 ± 1.0
Rattles	1.4 ± 1.1
Chest pain during coughing	1.5 ± 1.2
Dyspnea	1.1 ± 1.1
Cough severity VAS (mm), mean ± SD	58.2 ± 20.4
LCQ-acute score, mean ± SD
Total score	12.2 ± 3.3
Physical score	3.9 ± 1.0
Psychological score	4.4 ± 1.2
Social score	3.8 ± 1.3

*Data not provided by some participants.

Figure 1. Absolute frequency of treatment duration in all patients. Data not provided by some study participants.

Figure 2. BSS at baseline and during treatment (mean ± SD). *Wilcoxon p < .0001, two-sided alpha = .05. The number in the bars denotes the respective mean value. Lower N number at Day 4 is due to patients with treatment duration <4 days (N = 106) or due to data not provided.

Table 2. Key effectiveness assessments.

Key effectiveness assessments	BNO 1200
Number of eligible participants	730
Bronchitis Severity Score, mean ± SD
Total
Baseline	8.7 ± 3.8
Day 4	5.8 ± 3.3; p < .0001
End of treatment	2.4 ± 2.6; p < .0001
Cough
Baseline	2.8 ± 0.8
Day 4	1.9 ± 0.7
End of treatment	1.0 ± 0.7
Sputum
Baseline	1.9 ± 1.0
Day 4	1.6 ± 0.9
End of treatment	0.7 ± 0.7
Rattles
Baseline	1.4 ± 1.1
Day 4	0.9 ± 0.9
End of treatment	0.3 ± 0.6
Chest pain during coughing
Baseline	1.5 ± 1.2
Day 4	0.8 ± 0.9
End of treatment	0.2 ± 0.6
Dyspnea
Baseline	1.1 ± 1.1
Day 4	0.7 ± 0.9
End of treatment	0.2 ± 0.6
Cough severity VAS (mm)
Baseline	58.2 ± 20.4
Day 4	36.0 ± 18.9; p < .0001
End of treatment	14.9 ± 17.0; p < .0001
LCQ-acute, mean ± SD
Total
Baseline	12.2 ± 3.3
Day 4	15.3 ± 3.2; p < .0001
End of treatment	18.5 ± 2.7; p < .0001
Physical score
Baseline	3.9 ± 1.0
Day 4	4.9 ± 1.0
End of treatment	6.0 ± 0.9
Psychological score
Baseline	4.4 ± 1.2
Day 4	5.4 ± 1.2
End of treatment	6.3 ± 1.0
Social score
Baseline	3.8 ± 1.3
Day 4	5.0 ± 1.2
End of treatment	6.2 ± 1.0

p: statistically significant change versus baseline.

Figure 3. Course of cough severity measured on 100 mm VAS (Mean ± SD). *Wilcoxon p < .0001, two-sided alpha = .05. The number in the bars denotes the respective mean value. Lower N number at Day 4 is due to patients with treatment duration <4 days (N = 106) or due to data not provided.

Figure 4. Improvement of quality of life during treatment according to LCQ (mean ± SD). *Wilcoxon p < .0001, two-sided alpha = .05. The number in the bars denotes the respective mean value. Lower N number at Day 4 is due to patients with treatment duration <4 days (N = 106) or due to data not provided.

Figure 5. Patients’ assessments of effectiveness, treatment satisfaction and tolerability. Percentages of patients based on the categories “Very good”, “Good”, “Moderate”, “Poor” and “Insufficient”.